| ADMET-AI | – | – | – | – | • | – | – | – | – | – | – | – |
| AMES (mutagenicity) | – | – | – | – | • | – | • | – | – | – | – | – |
| ASAP Discovery Antiviral 2025 | – | – | – | • | • | – | – | – | – | – | – | – |
| Boltz-1 Structure Prediction Benchmark | – | – | – | • | – | – | – | – | – | – | – | – |
| CAFA5 | – | – | • | – | – | – | – | – | – | – | – | – |
| CAMEO weekly targets | – | – | – | • | – | – | – | – | – | – | – | – |
| canSAR | – | – | • | • | – | – | – | – | – | – | – | – |
| CAPRI Rounds | – | – | – | • | – | – | – | – | – | – | – | – |
| CASF-2016 | – | – | – | • | – | – | – | – | – | – | – | – |
| CASP15 | – | – | • | • | – | – | – | – | – | – | – | – |
| CASP16 | – | – | – | • | – | – | – | – | – | – | – | – |
| Cell Line Sensitivity Benchmark (CLSB) | – | – | • | – | • | – | – | – | – | – | – | – |
| ChEMBL | – | – | – | • | • | – | – | – | – | – | – | – |
| ClawBio Skill Correctness Bench | – | • | • | – | – | – | – | – | – | – | • | – |
| ClinBench Quarterly (Insilico) | – | – | – | – | – | – | – | – | • | • | • | – |
| ClinBench Quarterly — Q2 2026 | – | – | – | – | – | – | – | – | – | – | • | – |
| ClinTox | – | – | – | – | • | – | • | – | – | – | – | – |
| CoV-AbDab | – | – | – | • | – | – | – | – | – | – | – | – |
| CPTAC Proteogenomic Benchmarks | – | • | • | – | – | – | – | – | • | – | – | – |
| CRISPR Outcome Prediction Benchmark | – | – | – | • | – | – | – | – | – | – | – | – |
| CT-Outcome (TrialBench v2) | – | – | – | – | – | – | – | – | • | • | – | – |
| CZ Virtual Cell Challenge | • | – | • | – | – | – | – | – | – | – | – | – |
| DEKOIS 2.0 | – | – | – | • | – | – | – | – | – | – | – | – |
| DepMap (Cancer Dependency Map) | – | • | • | – | – | – | – | – | – | – | – | – |
| DILI / LD50 Zhu | – | – | – | – | • | – | • | – | – | – | – | – |
| DisGeNET | – | • | • | – | – | – | – | – | – | – | – | – |
| DMPK Integrated Benchmark | – | – | – | – | • | • | – | – | – | – | – | – |
| DOCKSTRING | – | – | – | • | – | – | – | – | – | – | – | – |
| DrugComb 2.0 Synergy Benchmark | – | – | – | – | • | • | – | – | – | – | – | – |
| DUD-E | – | – | – | • | – | – | – | – | – | – | – | – |
| FAERS (raw) | – | – | – | – | – | – | – | – | – | – | – | • |
| FLIP | – | – | • | – | – | • | – | – | – | – | – | – |
| Geneformer Eval | • | – | – | – | – | – | – | – | – | – | – | – |
| GNNBench-Drug 2026 | – | – | – | • | • | – | – | – | – | – | – | – |
| GuacaMol | – | – | – | – | • | • | – | – | – | – | – | – |
| hERG (cardio-tox) TDC | – | – | – | – | • | – | • | – | – | – | – | – |
| HINT / TrialBench | – | – | – | – | – | – | – | – | • | • | • | – |
| IgLM / AntiBERTa benchmarks | – | – | – | • | – | • | – | – | – | – | – | – |
| ISM Benchmarks: ADMET (Insilico) | – | – | – | – | • | – | • | – | – | – | – | – |
| ISM Benchmarks: GPCRs (Insilico) | – | – | – | • | • | – | – | – | – | – | – | – |
| LINCS L1000 / CMap | • | • | • | – | – | – | – | – | – | – | – | – |
| LIT-PCBA | – | – | – | • | – | – | – | – | – | – | – | – |
| Longevity Benchmark (Insilico) | – | • | • | – | – | – | – | – | – | – | – | • |
| Longevity Compound Benchmark | – | – | – | • | • | – | – | – | – | – | – | – |
| MatBench | – | – | – | – | – | • | – | – | – | – | – | – |
| MIMIC-IV Benchmark Tasks | – | – | – | – | – | – | – | – | – | • | • | • |
| MoleculeACE | – | – | – | – | • | – | – | – | – | – | – | – |
| MoleculeNet | – | – | – | • | • | – | – | – | – | – | – | – |
| MOSES | – | – | – | – | • | • | – | – | – | – | – | – |
| mRNA Design Benchmark (CodonBench 2026) | – | – | – | • | • | – | – | – | – | – | – | – |
| Obach PK Dataset | – | – | – | – | • | – | • | • | – | – | – | – |
| Observed Antibody Space (OAS) | – | – | – | • | • | – | – | – | – | – | – | – |
| OffSides / TWOSIDES | – | – | – | – | – | – | – | – | – | – | – | • |
| Open Problems: Perturbation Prediction | • | – | – | – | – | – | – | – | – | – | – | – |
| Open Systems Pharmacology / PK-Sim | – | – | – | – | – | – | • | • | – | – | – | – |
| Open Targets Platform | – | • | • | – | – | – | – | – | – | – | – | – |
| ORD Reaction Benchmark | – | – | – | – | – | • | – | – | – | – | – | – |
| PDBbind | – | – | – | • | • | – | – | – | – | – | – | – |
| PEER | – | – | • | – | – | • | – | – | – | – | – | – |
| PerturbBench | • | – | – | – | – | – | – | – | – | – | – | – |
| PINDER | – | – | – | • | – | – | – | – | – | – | – | – |
| PLINDER | – | – | – | • | – | – | – | – | – | – | – | – |
| PLINDER v2 Protein-Ligand Benchmark | – | – | – | • | – | – | – | – | – | – | – | – |
| Polaris ADMET | – | – | – | – | • | – | – | – | – | – | – | – |
| Polaris Biologics (Polyreactivity / SEC / Tm) | – | – | – | – | – | • | – | – | – | – | – | – |
| PoseBusters | – | – | – | • | – | – | – | – | – | – | – | – |
| Practical Molecular Optimization (PMO) | – | – | – | – | • | • | – | – | – | – | – | – |
| PrimeKG | – | • | • | – | – | – | – | – | – | – | – | – |
| Protein Design Benchmark 2026 | – | – | – | • | – | – | – | – | – | – | – | – |
| Protein Language Model Eval 2026 | • | – | – | • | – | – | – | – | – | – | – | – |
| ProteinGym | – | – | • | – | • | – | • | – | – | – | – | – |
| PubChem BioAssay | – | – | – | • | – | – | – | – | – | – | – | – |
| RxRx3 Phenomics Benchmark | – | – | – | • | • | – | – | – | – | – | – | – |
| SAbDab | – | – | – | • | • | • | – | – | – | – | – | – |
| scGPT Evaluation Suite | • | – | – | – | – | – | – | – | – | – | – | – |
| scImmuneBench | • | • | – | – | – | – | – | – | – | – | – | – |
| scPerturb | • | – | • | – | – | – | – | – | – | – | – | – |
| SIDER | – | – | – | – | – | – | • | – | – | – | – | • |
| Simcyp Validation Sets | – | – | – | – | – | – | • | • | • | – | – | – |
| STRING | – | • | • | – | – | – | – | – | – | – | – | – |
| TAPE | – | – | • | – | – | • | – | – | – | – | – | – |
| TargetBench (Insilico) | – | • | • | – | – | – | – | – | – | – | – | – |
| TDC ADMET Group | – | – | – | – | • | – | – | – | – | – | – | – |
| TDC DrugSyn (OncoPolyPharm + DrugComb_NCI60) | – | – | – | – | • | • | – | – | – | – | – | – |
| Therapeutic Antibody Design Benchmark 2026 | – | – | – | • | • | – | – | – | – | – | – | – |
| Tox21 | – | – | – | – | • | – | • | – | – | – | – | – |
| ToxCast | – | – | – | – | • | – | • | – | – | – | – | – |
| Trial Outcome Prediction (TOP) | – | – | – | – | – | – | – | – | – | • | • | – |
| USPTO-50K / USPTO-MIT (Retrosynthesis) | – | – | – | – | • | • | – | – | – | – | – | – |
| Virtual Cell Benchmark Suite 2026 | • | – | – | – | – | – | – | – | – | – | – | – |